Globally, the incidence of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) epidemics is increasing rapidly and has huge financial and emotional costs. The purpose of the current review article is to discuss the shared pathophysiological connections between AD and T2DM. Research findings are presented to underline the vital role that insulin plays in the brain’s neurotransmitters, homeostasis of energy, as well as memory capacity. The findings of this review indicate the existence of a mechanistic interplay between AD pathogenesis with T2DM and, especially, disrupted insulin signaling. AD and T2DM are interlinked with insulin resistance, neuroinflammation, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction and metabolic syndrome. Beta-amyloid, tau protein and amylin can accumulate in T2DM and AD brains. Given that the T2DM patients are not routinely evaluated in terms of their cognitive status, they are rarely treated for cognitive impairment. Similarly, AD patients are not routinely evaluated for high levels of insulin or for T2DM. Studies suggesting AD as a metabolic disease caused by insulin resistance in the brain also offer strong support for the hypothesis that AD is a type 3 diabetes.

Understanding the extent of human health risks with an emphasis on carcinogenesis development attributable to potentially toxic chemicals is critical to effective prevention and mitigation strategies. Chromium (Cr), mainly the hexavalent chromium (Cr (VI)), is a chemical associated with cancer when found in drinking water, making it a major public health issue. This study assessed a possible carcinogenic human health risk among the general population due to exposure to total or hexavalent chromium. We performed a systematic review of the international scientific literature, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol to determine the human risk of cancer mortality and morbidity. In total, 76 articles were checked for eligibility, 13 of which were included in the final systematic review. Only scientific articles from January 2000 to November 2022 published on PubMed were included. Data from both epidemiological ecological studies (Relative Risk and Rate Ratio—RR and Standardized Mortality Rate—SMR) and epidemiological case studies (Lifetime Cancer Risk—LCR, Incremental Lifetime Cancer Risk—ILCR, Cancer Risk—CR, Hazard Quotient—HQ, Hazard Index—HI, Health Risk Assessment—HRA, Disability-Adjusted Life Year—DALY, and Chronic Daily Intake Index—CDI) were included for the overall assessment of carcinogenicity in the general population. According to most articles, there is credible evidence that hexavalent chromium via water is indicated as a major contributor to the global burden of cancer in humans. Some of them emphasize malignant neoplasms in the lung, liver, stomach, and genitourinary system. Although the health index data of the case studies are based on a limited number of samples, they raise concerns about the possibility of an increase in the degree of carcinogenesis. However, there are significant limitations due to the lack of information on the dose and duration of exposure in the target group. Further research involving extensive analysis of the association of the two variables is needed, which depends on more complete information extraction and advanced methodologies.

Alzheimer’s disease (AD) is a rapidly growing disease that affects millions of people worldwide, therefore there is an urgent need for its early diagnosis and treatment. A huge amount of research studies are performed on possible accurate and reliable diagnostic biomarkers of AD. Due to its direct contact with extracellular space of the brain, cerebrospinal fluid (CSF) is the most useful biological fluid reflecting molecular events in the brain. Proteins and molecules that reflect the pathogenesis of the disease, e.g., neurodegeneration, accumulation of Abeta, hyperphosphorylation of tau protein and apoptosis may be used as biomarkers. The aim of the current manuscript is to present the most commonly used CSF biomarkers for AD as well as novel biomarkers. Three CSF biomarkers, namely total tau, phospho-tau and Abeta42, are believed to have the highest diagnostic accuracy for early AD diagnosis and the ability to predict AD development in mild cognitive impairment (MCI) patients. Moreover, other biomarkers such as soluble amyloid precursor protein (APP), apoptotic proteins, secretases and inflammatory and oxidation markers are believed to have increased future prospects.

The public health burden of type 2 diabetes mellitus and Alzheimer’s disease is steadily increasing worldwide, especially in the population of older adults. Epidemiological and clinical studies suggest a possible shared pathophysiology between the two diseases and an increased risk of AD in patients with type 2 diabetes mellitus. Therefore, in recent years, there has been a substantial interest in identifying the mechanisms of action of antidiabetic drugs and their potential use in Alzheimer’s disease. Human studies in patients with mild cognitive impairment and Alzheimer’s disease have shown that administration of some antidiabetic medications, such as intranasal insulin, metformin, incretins, and thiazolidinediones, can improve cognition and memory. This review aims to examine the latest evidence on antidiabetic medications as a potential candidate for the treatment of Alzheimer’s disease.

The quest for dietary patterns and supplements efficient in down-regulating prostate-specific antigen (PSA) concentrations among men with prostate cancer (PCa) or increased PCa risk has been long. Several antioxidants, including lycopene, selenium, curcumin, coenzyme Q10, phytoestrogens (including isoflavones and flavonoids), green tea catechins, cernitin, vitamins (C, E, D) and multivitamins, medicinal mushrooms (Ganoderma lucidum), fruit extracts (saw palmetto, cranberries, pomegranate), walnuts and fatty acids, as well as combined supplementations of all, have been examined in randomized controlled trials (RCTs) in humans, on the primary, secondary, and tertiary PCa prevention level. Despite the plethora of trials and the variety of examined interventions, the evidence supporting the efficacy of most dietary factors appears inadequate to recommend their use.